Maples Group Advises Biohaven Ltd on US$600 Million Investment by Oberland Capital

Maples and Calder, the Maples Group’s law firm, is pleased to have provided British Virgin Islands (BVI) and Cayman Islands counsel to Biohaven Ltd (“Biohaven”) in connection with a significant investment of up to US$600 million. The transaction closed on 30 April 2025.

Under the terms of transaction, Biohaven Therapeutics Ltd. and Oberland Capital Management LLC (“Oberland Capital”) entered into an agreement for the issuance of up to US$600 million in notes. The additional capital will provide Biohaven with significant financial resources for ongoing clinical trials across its full development portfolio.

Biohaven, a longstanding client of the Group, is a BVI-incorporated company listed on the New York Stock Exchange (NYSE), underscoring the Group’s continued access to sophisticated international capital markets and ability to provide unparalleled corporate services to its clients.

The Group’s multi-jurisdictional team consisted of BVI Managing Partner Chris Newton and Associate Chloe Harris from the BVI Corporate team and Partner Louise Cowley and Associate Kimberly Robinson from the Cayman Islands Corporate team.

The teams acted alongside Biohaven’s US counsel Covington & Burling LLP. Cooley LLP advised Oberland Capital.

The Maples Group has provided BVI counsel to Biohaven since its incorporation, following a spin-off included as part of a take private on which the firm also advised and its most recent public offerings in aggregate of US$517.5 million.